{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:13:12Z","timestamp":1794269592196,"version":"4.9.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","award":["IX-US-174-0206"],"award-info":[{"award-number":["IX-US-174-0206"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>There has been no clear consensus on the optimal consolidation periods following HBeAg seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients. Our study aimed to prospectively compare relapse rates between 12 months\u2019 and 18 months\u2019 consolidation periods to see whether or not there is beneficial durability of tenofovir disoproxil fumarate (TDF) therapy with longer consolidation periods.<\/jats:p>\n            <jats:p>We enrolled a total of 137 HBeAg-positive Asian CHB patients treated with TDF monotherapy. Forty-six patients achieved HBeAg SC. Then, they were randomly assigned to consolidation period of either 12 months (group A) or 18 months (group B). After stopping TDF therapy, all patients were followed up for 12 months.<\/jats:p>\n            <jats:p>Thirteen patients (56.5%) relapsed in group A and 12 patients (52.2%) relapsed in group B after 12 months\u2019 follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.958). Pretreatment HBsAg level is the only significant predictor for off-therapy recurrence by univariate analysis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.024). Baseline HBeAg &gt;1000\u200aS\/CO in group B patients were significantly less likely to relapse than those of group A (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.046). Baseline alanine aminotransferase (ALT) &gt;133\u200aU\/L could significantly predict occurrence of HBeAg SC (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.008; 95% CI: 0.545\u20130.763; AUC: 0.654).<\/jats:p>\n            <jats:p>Overall, a prolonged consolidation period has no positive effect on TDF therapy on sustained viral suppression in HBeAg-positive Asian CHB patients. However, a prolonged consolidation period was beneficial to patients with high baseline semi-quantitative HBeAg levels in terms of off-treatment durability. Baseline ALT\u200a&gt;\u200a133\u200aU\/L could significantly predict the occurrence of HBeAg SC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019907","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T03:35:02Z","timestamp":1588390502000},"page":"e19907","source":"Crossref","is-referenced-by-count":4,"title":["Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period"],"prefix":"10.1097","volume":"99","author":[{"given":"Chun-Hsiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Kuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruey-Chang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jeng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chieh","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Show Chwan Memorial Hospital, Changhua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tsung","family":"Tseng","sequence":"additional","affiliation":[{"name":"Committee of Medical Research, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-828674","article-title":"The natural history of chronic hepatitis B virus infection","volume":"24","author":"McMahon","year":"2004","journal-title":"Liver Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis, B., virus, infection","volume":"57","author":"Hu","year":"2012","journal-title":"J Hepatol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hep.28345","article-title":"AASLD practice guidelines: the past, the present, and the future","volume":"63","author":"Merriman","year":"2016","journal-title":"Hepatology"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/j.1440-1746.2005.03952.x","article-title":"Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy","volume":"20","author":"Byun","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","article-title":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G\u2217Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1016\/S0168-8278(08)60708-4","article-title":"Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine","volume":"48","author":"Poynard","year":"2008","journal-title":"J Hepatol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"R13-20230915","first-page":"669A","article-title":"HBeAg seroconversion is lower in Asian versus non-Asian patients during treatment of chronic hepatitis B with tenofovir or entecavir","volume":"58","author":"Jo","year":"2013","journal-title":"Hepatology"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0168-8278(02)00267-2","article-title":"Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation","volume":"37","author":"Lee","year":"2002","journal-title":"J Hepatol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2893.2009.01178.x","article-title":"Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"17","author":"Wang","year":"2010","journal-title":"J Viral Hepat"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1872-034X.2009.00560.x","article-title":"New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients","volume":"39","author":"Song","year":"2009","journal-title":"Hepatol Res"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/ajg.2009.200","article-title":"The duration of lamivudine therapy for chronic hepatitis B: cessation versus continuation of treatment after HBeAg seroconversion","volume":"104","author":"Fung","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1743-422X-9-239","article-title":"Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients","volume":"9","author":"Jin","year":"2012","journal-title":"Virol J"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/14740338.2012.672972","article-title":"Safety of long-term nucleos(t)ide treatment in chronic hepatitis B","volume":"11","author":"Ridruejo","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2011.04738.x","article-title":"Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy","volume":"34","author":"Liang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20230915","first-page":"2332","article-title":"Consolidation therapy for HBeAg positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study","volume":"68","author":"Dai","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1097\/MD.0000000000001341","article-title":"Durability of nucleos(t)ide analogues treatment in patients with chronic hepatitis B","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/380965","article-title":"Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection","volume":"38","author":"Ito","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2893.2002.00357.x","article-title":"Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion","volume":"9","author":"Lee","year":"2002","journal-title":"J Viral Hepat"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcv.2009.04.006","article-title":"Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression","volume":"45","author":"Yeh","year":"2009","journal-title":"J Clin Virol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0168-8278(96)80263-7","article-title":"The value of quantitative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection","volume":"24","author":"Jardi","year":"1996","journal-title":"J Hepatol"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3329\/bmrcb.v34i2.1173","article-title":"HBeAg\/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers","volume":"34","author":"Rabbi","year":"2008","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"R35-20230915","first-page":"110","article-title":"Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg\/anti-HBe, and liver function tests","volume":"33","author":"Hasan","year":"2002","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/1319-3767.121035","article-title":"Correlation between hepatitis B surface antigen titers and HBV DNA levels","volume":"19","author":"Alghamdi","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"Determinants for sustained HBeAg response to lamivudine therapy","volume":"38","author":"Chien","year":"2003","journal-title":"Hepatology"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:55:41Z","timestamp":1694818541000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019907"}},"subtitle":["A prospective randomized cohort study"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":38,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019907","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}